Supplements

Timeline Mitopure Urolithin A Supplement Softgels

Two softgels (500mg) of Mitopure, Timeline's form of Urolithin A. Vegan, non-GMO, NSF Certified for Sport, Clean Label Project Verified and made in the USA, per the listing.

Per serving · from the listing

Urolithin A (Mitopure)500mg2 softgels

See it on Amazon

Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition.

Not medical advice.

Serving and certifications from the Amazon listing; check the box you buy.

What the published trials found

First-in-human trial: safe and well tolerated at 250–1,000 mg a day for 4 weeks in 60 older adults. No efficacy claim. PubMed ›
Adults 65–90, 1,000 mg a day for 4 months: both primary endpoints (6-minute walk, muscle ATP) were missed. Muscle endurance improved versus placebo at two months (a secondary outcome; hand P<.01 by a post hoc test, leg P=.05), not at four. Safe and well tolerated. Company-funded, with 14 secondary outcomes and no correction for multiple comparisons. PubMed ›
Untrained, overweight adults 40–64, 4 months: the primary endpoint (peak cycling power) was missed. Hamstring strength rose about 12% at 500 mg while the placebo group lost about 10%; the difference was significant (p=0.027; secondary, uncorrected), though the rise alone was not significant from baseline. The VO2 and 6-minute-walk gains were within-group only, not significant versus placebo. PubMed ›
A small 8-week pilot in 20 trained men: more reps to failure and more isometric strength than placebo (p=0.011 / 0.048); no change in one-rep max. Unregistered, with no power calculation. PubMed ›
42 highly trained male distance runners, 4 weeks: the 3,000 m time trial was not improved (p=0.12). Perceived exertion was lower (p=0.02) and a post-exercise muscle-damage marker was lower (p<0.0001). Company-funded, with company employees among the authors. PubMed ›
50 healthy middle-aged adults, 1,000 mg a day for 4 weeks: the first Urolithin A trial to meet its primary endpoints — and both are immune-cell markers rather than health outcomes. CD8+ T cells shifted toward a naive-like, less exhausted profile (+0.50 percentage points, P=0.04) and their fat-burning capacity rose (+14.7 percentage points, P=0.006). Four weeks, no clinical endpoint; company-funded. PubMed ›
10 patients with heart failure and reduced ejection fraction, 500 mg twice a day in a crossover trial: no effect on any heart measure, or on pro-BNP, glucose or CRP. HDL cholesterol rose slightly (p=0.026). A disease population, not a use for a supplement — it is here because a null result belongs in the record. PubMed ›
Whether your own gut makes Urolithin A varies: of 100 healthy adults only 12% had detectable levels at the start, and about 40% produced it after a glass of pomegranate juice. Taking it directly gave more than six times the exposure. This trial measured exposure, not benefit; company-funded. PubMed ›

Six of these eight trials name Amazentis SA, the company behind Mitopure, as funder or sponsor; two carry no funding statement at all. Summaries are PearlQuant's reading of each paper; follow the PubMed links for the originals.